Ipamorelin and CJC-1295 (No DAC): two different receptors
Compound Science
Research Peptide Learning Centre · Published 7 October 2026 · 4 min read
How Ipamorelin and CJC-1295 (No DAC) are studied on the growth-hormone axis: two different receptors, what the studies actually measured, the DAC distinction, and plain limits.
Ipamorelin and CJC-1295 (No DAC) are often discussed together because both are studied in relation to the growth-hormone axis. They act at different receptors, and the published research is laboratory and early-stage. This guide organises what each compound has been studied for, what the studies actually measured, and where the limits are. It is educational and is not a route to personal use or a determination that any activity is permitted.
Two different receptors on the growth-hormone axis
Growth-hormone release is influenced by more than one signal. Ipamorelin is studied as a selective agonist of the growth-hormone secretagogue receptor (GHS-R1a), the receptor for ghrelin. CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) and is studied at the GHRH receptor. Describing the two as acting on “the same system” loses an important distinction: they are examined at separate receptors, and a result for one is not evidence for the other.
What the Ipamorelin research examined
The first detailed characterisation described Ipamorelin as a pentapeptide that released growth hormone in animal models with greater selectivity than some earlier secretagogues, without the marked increases in ACTH and cortisol those compounds produced (Raun et al., 1998). A later study modelled its pharmacokinetics and the growth-hormone response in human volunteers (Gobburu et al., 1999). These describe receptor pharmacology and a measured hormone response; they are not evidence that the material changes muscle, body composition or recovery in people. Ipamorelin is not an approved medicine, and its clinical development did not lead to approval.
For the current listing, see the Ipamorelin research profile, which records its identity and documentation status.
What the CJC-1295 research examined, and the DAC distinction
“CJC-1295” covers two related forms. The long-acting version carries a Drug Affinity Complex (DAC) modification that greatly extends half-life; in healthy adults it prolonged growth-hormone and IGF-I secretion (Teichman et al., 2006). The product described here is the no-DAC form, also called Modified GRF 1-29, which lacks that modification and is shorter-acting. When reading CJC-1295 literature, check which form a study used before applying its result; the two are not interchangeable, and much of the published clinical data concerns the long-acting DAC version.
See the CJC-1295 (No DAC) research profile for the identity recorded on the listing.
Reading the records before comparing
For any laboratory comparison, the useful question is whether the material, its documentation and its supply terms meet the project’s requirements. Record the compound’s identity, match the proposed lot to its analytical report, and note the laboratory, method, result and date. Keep analytical suitability and commercial terms in separate columns: a prompt reply or an attractive price does not answer an identity question, and a report does not confirm a delivery commitment.
A research-use label does not settle regulatory questions. Health Canada’s advisory on online injectable peptides states that research-use wording does not exempt products from regulatory requirements and warns consumers against using unauthorized peptide drugs. Read the advisory. Our COA guide and the Certificate Library cover the analytical side of this review.
Common questions
Do Ipamorelin and CJC-1295 do the same thing?
They are studied at different receptors: Ipamorelin at the ghrelin (GHS-R1a) receptor and CJC-1295 at the GHRH receptor. Research on one is not evidence for the other.
Is the “No DAC” form the same as regular CJC-1295?
No. The no-DAC form (Modified GRF 1-29) lacks the half-life-extending Drug Affinity Complex, so it is shorter-acting. Much published CJC-1295 clinical data used the long-acting DAC form.
Why are the two discussed together?
Because they are studied in relation to the same growth-hormone axis from two different receptors. That shared subject is why researchers compare them; it does not mean a result for one transfers to the other, and no combined effect is claimed here.
Does any of this support personal use?
No. These materials are presented for laboratory and analytical research only, and this guide is not a treatment or personal-use protocol.
Sources and scope
- Raun et al., 1998 — Ipamorelin, the first selective growth hormone secretagogue (Eur J Endocrinol)
- Gobburu et al., 1999 — Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (Pharm Res)
- Teichman et al., 2006 — CJC-1295, a long-acting GHRH analog, in healthy adults (JCEM)
- Health Canada: advisory on unauthorized injectable peptides
Published research describes the material and conditions used by its authors. It does not test, certify or endorse Reforge inventory. This guide is educational and is not a treatment or personal-use protocol.